The purpose of this case study summary is to briefly describe how stakeholders have used the prescriptions dispensed in the community publication to inform analytical, reporting and contract negotiation activities.
A benefits case study describing how national stakeholders have used HSCIC's immunisation statistics to help drive improvements in immunisation services and inform decisions when managing disease outbreaks
A benefits case study describing how national stakeholders have used HSCIC's immunisation statistics to help drive improvements in immunisation services and inform decisions when managing disease outbreaks
A benefits case study describing how Diabetes UK has used HSCIC's data and statistical outputs to inform the Putting Feet First campaign. https://www.diabetes.org.uk/Get_involved/Campaigning/Our-campaigns/Putting-feet-first/
The document discusses the importance of manufacturing to the UK pharmaceutical industry and the life sciences sector. It outlines the goals of the Medicines Manufacturing Industry Partnership (MMIP) in making the UK an attractive location for medicines manufacturing through initiatives like skills development programs. The document also notes industry's significant financial contributions to the NHS through the Pharmaceutical Price Regulation Scheme, and the importance of ensuring a regulatory framework that supports innovation as the UK leaves the EU.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
Trailblazing scientists who are the backbone of our industry. These are the people that discover the molecules and develop the medicines to tackle the toughest diseases we face in society.
Medicines and vaccines have helped deliver improvements in patient health. History shows us the great advances we have made - today we continue to see the potential to eradicate disease and improve health outcomes when we invest in science and adopt and use new medicines.
Mirjam Maeusezahl: Joint External Evaluations (JEE) – Country experiences: Sw...THL
The document discusses Switzerland's participation in the Joint External Evaluation (JEE) conducted by the World Health Organization. It provides details on Switzerland's implementation of the International Health Regulations, the timeline and milestones of the JEE process, and lessons learned. Key results showed room for improvement in antimicrobial resistance detection and response as well as strengthening surveillance systems for zoonotic diseases. Switzerland adapted the WHO National Action Plan template to monitor progress in addressing JEE recommendations internally.
A benefits case study describing how national stakeholders have used HSCIC's immunisation statistics to help drive improvements in immunisation services and inform decisions when managing disease outbreaks
A benefits case study describing how national stakeholders have used HSCIC's immunisation statistics to help drive improvements in immunisation services and inform decisions when managing disease outbreaks
A benefits case study describing how Diabetes UK has used HSCIC's data and statistical outputs to inform the Putting Feet First campaign. https://www.diabetes.org.uk/Get_involved/Campaigning/Our-campaigns/Putting-feet-first/
The document discusses the importance of manufacturing to the UK pharmaceutical industry and the life sciences sector. It outlines the goals of the Medicines Manufacturing Industry Partnership (MMIP) in making the UK an attractive location for medicines manufacturing through initiatives like skills development programs. The document also notes industry's significant financial contributions to the NHS through the Pharmaceutical Price Regulation Scheme, and the importance of ensuring a regulatory framework that supports innovation as the UK leaves the EU.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
Trailblazing scientists who are the backbone of our industry. These are the people that discover the molecules and develop the medicines to tackle the toughest diseases we face in society.
Medicines and vaccines have helped deliver improvements in patient health. History shows us the great advances we have made - today we continue to see the potential to eradicate disease and improve health outcomes when we invest in science and adopt and use new medicines.
Mirjam Maeusezahl: Joint External Evaluations (JEE) – Country experiences: Sw...THL
The document discusses Switzerland's participation in the Joint External Evaluation (JEE) conducted by the World Health Organization. It provides details on Switzerland's implementation of the International Health Regulations, the timeline and milestones of the JEE process, and lessons learned. Key results showed room for improvement in antimicrobial resistance detection and response as well as strengthening surveillance systems for zoonotic diseases. Switzerland adapted the WHO National Action Plan template to monitor progress in addressing JEE recommendations internally.
Antibiotic Guardian Birmingham Workshop4 All of Us
Antibiotic resistance is one of the biggest threats facing us today!
European Antibiotic Awareness Day (EAAD) is part of the UK 5 Year Antimicrobial Resistance Strategy 2013 to 2018, which focuses on antibiotics and sets out actions to slow the development and spread of antimicrobial resistance.
This year, to run in line with EAAD; Public Health England has established the Antibiotic Guardian pledge campaign. It calls on everyone in the UK, the public and healthcare community to become antibiotics guardian by choosing one simple pledge about how they will make better use of these vital medicines.
To ensure that the information and knowledge on Antibiotic Stewardship is disseminated to those practising healthcare across the nation, a series of awareness and educational events have been developed. These educational workshop events, to be held in Leeds, Birmingham and London, will provide guidance, resources and information for practitioners on topics associated with antibiotic awareness. The events will provide an opportunity to understand how you and your organisation can support combat the global challenge faced by antibiotic resistance whilst gaining advice, support and resources to inform patients and staff.
The document outlines the opportunities and challenges presented by big data in healthcare. It notes that vast amounts of data are now being generated from sources like genome sequencing, electronic health records, social media, and patient websites. However, simply having large datasets does not guarantee value; the data needs to be analyzed and linked together to generate insights. The document discusses four levels of big data applications from processing large volumes of data to complex modeling. It also examines challenges like developing robust governance, embracing new data uses, overcoming data fragmentation, ensuring data quality and standards, developing innovative analytic methods, addressing skills shortages, and achieving returns on investment. The goal is to improve patient outcomes and healthcare cost-effectiveness through big data.
This research explores the feasibility of introducing an Outcome-Based Payment approach for new cancer drugs in England. A literature review explored the current funding landscape in England, the available evidence on existing OBP schemes internationally, and
which outcomes cancer patients value most. Two focus groups and an online survey with patients and carers, as well as interviews with NHS and government stakeholders, healthcare
professionals, and pharmaceutical industry representatives, provided additional evidence on the feasibility and suitability of OBP schemes
Cdc get smart week resident presentation 2014katejohnpunag
This document discusses antibiotic overuse and resistance. It notes that overuse of antibiotics can lead to adverse drug events, antibiotic resistance, and Clostridium difficile infections. It summarizes the 2013 CDC Threat Report on antibiotic resistance and lists several "superbugs" as major threats. The document advocates for antibiotic stewardship programs and lists seven ways healthcare providers can improve antibiotic prescribing practices to help address the growing crisis of antibiotic resistance.
On Tuesday, March 31, 2020, the FDA announced a new program aimed at facilitating research and development of COVID-19 treatments. With over 920,000 confirmed cases globally, the Coronavirus pandemic is forcing the FDA to create a rapid pathway for treatments. The new Coronavirus Treatment Acceleration Program (CTAP) is the FDA’s answer to the massive surge of inquiries across the public, academic, and private sectors looking for ways to treat COVID-19...
OS20 - Factors influencing decision-making for foot-and-mouth disease contro...EuFMD
The document summarizes factors that influence decision-making for foot-and-mouth disease control in Kenya. Key informant interviews revealed inconsistent prioritization of animal disease control, separate lines of strategic guidance and accountability/budgeting, and private veterinarians involved in disease reporting and vaccination outside of official guidance and accountability. There are opportunities to provide more relevant disease data to farmers and veterinarians and ensure information flows in both directions. Strengthening FMD control could include reinforcing programmatic strengths through a participatory national strategy, integrated public-private partnerships, and accountability mechanisms that promote two-way communication.
Presentation on approaches to measure medicine prices and price components, by Marg Ewen, Health Action International, at the launch of the Medicines Transparency Alliance, London 15 May 2008
This document summarizes a presentation by Ricardo Baptista Leite on time trends in health for the next decade. It discusses the evolution of healthcare in Portugal, challenges facing the Portuguese national health service like an aging population and non-communicable diseases. It also covers trends toward value-based and patient-centered care, the role of information and communication technologies in areas like precision medicine, and ensuring the financial sustainability of health systems.
The Innovation and Technology Tariff (ITT) aims to incentivize adoption of transformative innovations in the NHS by streamlining pricing and reimbursement. For 2017-19, the first year of the ITT, six themes have been identified that could provide innovation benefits to the NHS at scale. These themes include guided mediolateral episiotomy to minimize obstetric injuries, reducing medication errors, preventing ventilator-associated pneumonia, managing COPD remotely, treating C. difficile infection with frozen fecal transplants, and treating enlarged prostates as outpatients. The ITT operates under both an incentive-based pricing model and a zero-cost model where NHS England covers the cost of approved innovations.
This document discusses a feasibility study examining whether decisions by the UK's National Institute for Health and Care Excellence (NICE) influence decisions by health technology assessment bodies in other countries. The study analyzed 29 drug-indication pairs assessed by NICE and other countries' HTAs. The results suggest NICE decisions are related to subsequent HTAs in other countries. Drugs without positive NICE recommendations had a higher probability of being not recommended by other HTAs. Additionally, the number of fully reimbursed drugs was higher before versus after NICE assessment. The consideration of NICE decisions may increase the likelihood of other HTAs issuing negative decisions. However, the small sample size means results must be interpreted cautiously and more research is needed.
The UK AMR Diagnostic Collaborative aims to maximize the use of diagnostic technology to tackle antimicrobial resistance. It provides single point of focus and leadership for the complex UK diagnostic system. Key areas of focus include diagnostic stewardship, innovation, and addressing unwarranted variation. Upcoming milestones include a national blood culture survey and engagement with industry to accelerate innovative solutions. The collaborative works in partnership across agencies to ensure a responsive diagnostic system.
The document summarizes healthcare systems in the United Kingdom and Germany. It discusses funding models for prescription drugs in England, including Clinical Commissioning Groups (CCGs) and the National Institute for Health and Care Excellence (NICE). It also describes the Cancer Drugs Fund in England and reforms to drug pricing in Germany under the AMNOG process.
National Program on Prevention and Control of Infection and Antimicrobial Resistance – PPCIRA / PORTUGAL
Before 2013, Portugal had a high prevalence of hospital-acquired infections and high antimicrobial consumption compared to other EU countries. Carbapenem and quinolone use was among the highest. Through the PPCIRA program established in 2013, Portugal implemented initiatives like establishing epidemiological surveillance, antimicrobial stewardship programs, and a standard precautions campaign. These efforts led to reductions in antimicrobial consumption in both hospital and community settings, lower rates of methicillin-resistant Staphylococcus aureus, and decreases in some hospital-acquired infections like surgical site infections and infections in neonatal and adult ICUs.
1. The director of the EMCDDA discussed the evolution of HIV, drugs, and risk behavior in Europe based on lessons learned over decades. New HIV infections attributed to injecting drug use have declined significantly since the 1990s due to effective drug treatment and prevention programs.
2. However, regional disparities remain, and new outbreaks have been linked to stimulant use and new psychoactive substances. Maintaining prevention services and reaching vulnerable groups who are not in care will be important to address ongoing challenges.
3. Going forward, the EMCDDA aims to maintain understanding of drug use trends, identify new health threats to support rapid responses, promote effective interventions, and support policy development - all to contribute to
Global consultation on environmentally friendly procurement in the health sectorUNDP Eurasia
Dr. Christoph Hamelmann is the Regional Practice Leader for HIV at UNDP Europe and Central Asia. He presented at a global consultation on environmentally friendly procurement in the health sector. The presentation discussed establishing standards for "green" health sector procurement and capacity building for procurement officers and suppliers on sustainable practices. It also outlined a joint UN program to promote environmentally sound procurement policies across UN agencies for the health sector. The program aims to research best practices, train stakeholders, and increase awareness of sustainable procurement initiatives.
The document discusses European Union actions related to newborn screening for rare diseases. It provides background on EU health policy and legislation regarding rare diseases. It then summarizes an evaluation launched in 2009 on newborn screening practices for rare diseases across EU member states. The evaluation includes reports on current practices, an expert opinion on developing EU policies, and establishing an expert network on newborn screening.
The document discusses European policies and national plans for rare diseases. It provides details on:
- The 1999 European regulation on orphan medicinal products and 2008 EU communication on rare diseases that set out a community strategy.
- The 2009 EU recommendation that member states develop national rare disease plans or strategies by 2013 addressing areas like care, research, and social services.
- Updates from EUROPLAN 2015 on the status of national rare disease plans in 24 European countries.
- Core indicators proposed by the EU to monitor national rare disease plans across areas like governance, care centers, research, and funding.
This document summarizes a presentation given at an ISPOR conference on multi-indication pricing. It discusses the challenges of setting one price for a drug across multiple indications when the value may differ based on the indication. It provides examples showing large price differences between indications for the same drugs in different countries. Stakeholders generally support prices reflecting relative value but have concerns about implementation. UK workshop participants felt more collaboration would be needed between stakeholders if the UK pursued multi-indication pricing schemes.
The BRIDGE Health project involves 31 institutes from 16 European countries. It aims to develop a strategic policy paper and technical blueprints for a future integrated European health information system covering both public health and healthcare. The project will disseminate results through technical reports, workshops, and meetings to target audiences like policymakers, researchers, and the general public. It seeks to ensure sustainability of health information activities and enhance synergy between domains like population health monitoring, disease registries, and clinical data collection.
The document summarizes the evolution of the UK healthcare system and its experimentation with value-based approaches. It discusses:
1) The centralized NHS system and the influential role of NICE in determining cost-effectiveness of treatments.
2) Recent initiatives to introduce pay-for-performance models and identify variations in care pathways to increase value.
3) The challenges of clearly defining and measuring "value" given mixed results from these experiments and structural healthcare reforms that fragmented the system.
The document discusses the essential drugs concept launched by WHO in 1977 to make a set of minimum medical needs available and affordable. It summarizes the history and role of E-DRUG, an English language discussion group started in 1995 to support the concept of essential drugs by facilitating communication among health professionals. It also describes related discussion groups in French and Spanish and initiatives to create an international network of drug information centers and country-focused groups.
Antibiotic Guardian Birmingham Workshop4 All of Us
Antibiotic resistance is one of the biggest threats facing us today!
European Antibiotic Awareness Day (EAAD) is part of the UK 5 Year Antimicrobial Resistance Strategy 2013 to 2018, which focuses on antibiotics and sets out actions to slow the development and spread of antimicrobial resistance.
This year, to run in line with EAAD; Public Health England has established the Antibiotic Guardian pledge campaign. It calls on everyone in the UK, the public and healthcare community to become antibiotics guardian by choosing one simple pledge about how they will make better use of these vital medicines.
To ensure that the information and knowledge on Antibiotic Stewardship is disseminated to those practising healthcare across the nation, a series of awareness and educational events have been developed. These educational workshop events, to be held in Leeds, Birmingham and London, will provide guidance, resources and information for practitioners on topics associated with antibiotic awareness. The events will provide an opportunity to understand how you and your organisation can support combat the global challenge faced by antibiotic resistance whilst gaining advice, support and resources to inform patients and staff.
The document outlines the opportunities and challenges presented by big data in healthcare. It notes that vast amounts of data are now being generated from sources like genome sequencing, electronic health records, social media, and patient websites. However, simply having large datasets does not guarantee value; the data needs to be analyzed and linked together to generate insights. The document discusses four levels of big data applications from processing large volumes of data to complex modeling. It also examines challenges like developing robust governance, embracing new data uses, overcoming data fragmentation, ensuring data quality and standards, developing innovative analytic methods, addressing skills shortages, and achieving returns on investment. The goal is to improve patient outcomes and healthcare cost-effectiveness through big data.
This research explores the feasibility of introducing an Outcome-Based Payment approach for new cancer drugs in England. A literature review explored the current funding landscape in England, the available evidence on existing OBP schemes internationally, and
which outcomes cancer patients value most. Two focus groups and an online survey with patients and carers, as well as interviews with NHS and government stakeholders, healthcare
professionals, and pharmaceutical industry representatives, provided additional evidence on the feasibility and suitability of OBP schemes
Cdc get smart week resident presentation 2014katejohnpunag
This document discusses antibiotic overuse and resistance. It notes that overuse of antibiotics can lead to adverse drug events, antibiotic resistance, and Clostridium difficile infections. It summarizes the 2013 CDC Threat Report on antibiotic resistance and lists several "superbugs" as major threats. The document advocates for antibiotic stewardship programs and lists seven ways healthcare providers can improve antibiotic prescribing practices to help address the growing crisis of antibiotic resistance.
On Tuesday, March 31, 2020, the FDA announced a new program aimed at facilitating research and development of COVID-19 treatments. With over 920,000 confirmed cases globally, the Coronavirus pandemic is forcing the FDA to create a rapid pathway for treatments. The new Coronavirus Treatment Acceleration Program (CTAP) is the FDA’s answer to the massive surge of inquiries across the public, academic, and private sectors looking for ways to treat COVID-19...
OS20 - Factors influencing decision-making for foot-and-mouth disease contro...EuFMD
The document summarizes factors that influence decision-making for foot-and-mouth disease control in Kenya. Key informant interviews revealed inconsistent prioritization of animal disease control, separate lines of strategic guidance and accountability/budgeting, and private veterinarians involved in disease reporting and vaccination outside of official guidance and accountability. There are opportunities to provide more relevant disease data to farmers and veterinarians and ensure information flows in both directions. Strengthening FMD control could include reinforcing programmatic strengths through a participatory national strategy, integrated public-private partnerships, and accountability mechanisms that promote two-way communication.
Presentation on approaches to measure medicine prices and price components, by Marg Ewen, Health Action International, at the launch of the Medicines Transparency Alliance, London 15 May 2008
This document summarizes a presentation by Ricardo Baptista Leite on time trends in health for the next decade. It discusses the evolution of healthcare in Portugal, challenges facing the Portuguese national health service like an aging population and non-communicable diseases. It also covers trends toward value-based and patient-centered care, the role of information and communication technologies in areas like precision medicine, and ensuring the financial sustainability of health systems.
The Innovation and Technology Tariff (ITT) aims to incentivize adoption of transformative innovations in the NHS by streamlining pricing and reimbursement. For 2017-19, the first year of the ITT, six themes have been identified that could provide innovation benefits to the NHS at scale. These themes include guided mediolateral episiotomy to minimize obstetric injuries, reducing medication errors, preventing ventilator-associated pneumonia, managing COPD remotely, treating C. difficile infection with frozen fecal transplants, and treating enlarged prostates as outpatients. The ITT operates under both an incentive-based pricing model and a zero-cost model where NHS England covers the cost of approved innovations.
This document discusses a feasibility study examining whether decisions by the UK's National Institute for Health and Care Excellence (NICE) influence decisions by health technology assessment bodies in other countries. The study analyzed 29 drug-indication pairs assessed by NICE and other countries' HTAs. The results suggest NICE decisions are related to subsequent HTAs in other countries. Drugs without positive NICE recommendations had a higher probability of being not recommended by other HTAs. Additionally, the number of fully reimbursed drugs was higher before versus after NICE assessment. The consideration of NICE decisions may increase the likelihood of other HTAs issuing negative decisions. However, the small sample size means results must be interpreted cautiously and more research is needed.
The UK AMR Diagnostic Collaborative aims to maximize the use of diagnostic technology to tackle antimicrobial resistance. It provides single point of focus and leadership for the complex UK diagnostic system. Key areas of focus include diagnostic stewardship, innovation, and addressing unwarranted variation. Upcoming milestones include a national blood culture survey and engagement with industry to accelerate innovative solutions. The collaborative works in partnership across agencies to ensure a responsive diagnostic system.
The document summarizes healthcare systems in the United Kingdom and Germany. It discusses funding models for prescription drugs in England, including Clinical Commissioning Groups (CCGs) and the National Institute for Health and Care Excellence (NICE). It also describes the Cancer Drugs Fund in England and reforms to drug pricing in Germany under the AMNOG process.
National Program on Prevention and Control of Infection and Antimicrobial Resistance – PPCIRA / PORTUGAL
Before 2013, Portugal had a high prevalence of hospital-acquired infections and high antimicrobial consumption compared to other EU countries. Carbapenem and quinolone use was among the highest. Through the PPCIRA program established in 2013, Portugal implemented initiatives like establishing epidemiological surveillance, antimicrobial stewardship programs, and a standard precautions campaign. These efforts led to reductions in antimicrobial consumption in both hospital and community settings, lower rates of methicillin-resistant Staphylococcus aureus, and decreases in some hospital-acquired infections like surgical site infections and infections in neonatal and adult ICUs.
1. The director of the EMCDDA discussed the evolution of HIV, drugs, and risk behavior in Europe based on lessons learned over decades. New HIV infections attributed to injecting drug use have declined significantly since the 1990s due to effective drug treatment and prevention programs.
2. However, regional disparities remain, and new outbreaks have been linked to stimulant use and new psychoactive substances. Maintaining prevention services and reaching vulnerable groups who are not in care will be important to address ongoing challenges.
3. Going forward, the EMCDDA aims to maintain understanding of drug use trends, identify new health threats to support rapid responses, promote effective interventions, and support policy development - all to contribute to
Global consultation on environmentally friendly procurement in the health sectorUNDP Eurasia
Dr. Christoph Hamelmann is the Regional Practice Leader for HIV at UNDP Europe and Central Asia. He presented at a global consultation on environmentally friendly procurement in the health sector. The presentation discussed establishing standards for "green" health sector procurement and capacity building for procurement officers and suppliers on sustainable practices. It also outlined a joint UN program to promote environmentally sound procurement policies across UN agencies for the health sector. The program aims to research best practices, train stakeholders, and increase awareness of sustainable procurement initiatives.
The document discusses European Union actions related to newborn screening for rare diseases. It provides background on EU health policy and legislation regarding rare diseases. It then summarizes an evaluation launched in 2009 on newborn screening practices for rare diseases across EU member states. The evaluation includes reports on current practices, an expert opinion on developing EU policies, and establishing an expert network on newborn screening.
The document discusses European policies and national plans for rare diseases. It provides details on:
- The 1999 European regulation on orphan medicinal products and 2008 EU communication on rare diseases that set out a community strategy.
- The 2009 EU recommendation that member states develop national rare disease plans or strategies by 2013 addressing areas like care, research, and social services.
- Updates from EUROPLAN 2015 on the status of national rare disease plans in 24 European countries.
- Core indicators proposed by the EU to monitor national rare disease plans across areas like governance, care centers, research, and funding.
This document summarizes a presentation given at an ISPOR conference on multi-indication pricing. It discusses the challenges of setting one price for a drug across multiple indications when the value may differ based on the indication. It provides examples showing large price differences between indications for the same drugs in different countries. Stakeholders generally support prices reflecting relative value but have concerns about implementation. UK workshop participants felt more collaboration would be needed between stakeholders if the UK pursued multi-indication pricing schemes.
The BRIDGE Health project involves 31 institutes from 16 European countries. It aims to develop a strategic policy paper and technical blueprints for a future integrated European health information system covering both public health and healthcare. The project will disseminate results through technical reports, workshops, and meetings to target audiences like policymakers, researchers, and the general public. It seeks to ensure sustainability of health information activities and enhance synergy between domains like population health monitoring, disease registries, and clinical data collection.
The document summarizes the evolution of the UK healthcare system and its experimentation with value-based approaches. It discusses:
1) The centralized NHS system and the influential role of NICE in determining cost-effectiveness of treatments.
2) Recent initiatives to introduce pay-for-performance models and identify variations in care pathways to increase value.
3) The challenges of clearly defining and measuring "value" given mixed results from these experiments and structural healthcare reforms that fragmented the system.
The document discusses the essential drugs concept launched by WHO in 1977 to make a set of minimum medical needs available and affordable. It summarizes the history and role of E-DRUG, an English language discussion group started in 1995 to support the concept of essential drugs by facilitating communication among health professionals. It also describes related discussion groups in French and Spanish and initiatives to create an international network of drug information centers and country-focused groups.
Investigation of the accessibility and affordability of medicines in speciali...Cornelis Jan Diepeveen
The document discusses a study investigating the accessibility and affordability of medicines in specialist medical care in the Netherlands. It provides context on key players in the supply chain and financing of these medicines. The study included interviews, literature reviews, surveys, and data analysis. It examines current expenditures on these medicines, how costs may develop, and ways to better ensure accessibility and affordability. The summary provides high-level information on the purpose, methodology, and focus of the study without copying significant text.
Market access database with more than 2,000 reports that provide companies with a roadmap regarding the steps to follow to succeed in the Spanish market
The Health Innovation Network Polypharmacy Programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, SBAR Patient Engagement Tool, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
Each pound invested in cancer-related research by taxpayers and charities in the UK returns around 40 pence annually to the UK economy. This study estimated the economic benefits of public and charitable funding for cancer research in the UK between 1970-2009. It found that this investment of £15 billion produced health benefits valued at £124 billion for UK patients from 1991-2010 through reduced cancer incidence, early detection from screening, and improved survival. Accounting for the average 15 year time lag between investment and health impacts, as well as the proportion of research attributable to the UK, the study estimates cancer research has generated a 10% rate of return. Including indirect economic spillovers, the total estimated annual rate of return is 40%, meaning
Health-care interventions to promote and assist tobacco cessation: a review o...Georgi Daskalov
This document reviews the efficacy, effectiveness, and affordability of healthcare interventions for tobacco cessation. It finds that brief advice from healthcare workers can promote smoking cessation and is affordable globally. Telephone and text support programs and printed materials can assist with quit attempts and are globally affordable. Face-to-face behavioral support increases quit rates for cigarettes and smokeless tobacco and is affordable in middle- and high-income countries. Several medications can aid quitting when combined with behavioral support, with cytisine and nortriptyline being globally affordable. Brief advice, telephone/text support, self-help materials, cytisine, and nortriptyline are identified as globally affordable tobacco cessation interventions.
Dr. Lauri Hicks - Out-Patient Antibiotic Resistance (AMR) IssuesJohn Blue
Out-Patient Antibiotic Resistance (AMR) Issues - Dr. Lauri Hicks, Commander, U.S. Public Health Service, Medical Epidemiologist, Respiratory Diseases Branch; Medical Director, Get smart: Know When Antibiotic Work Program; Centers for Disease Control and Prevention (CDC), from the 2015 NIAA Antibiotic Symposium - Stewardship: From Metrics to Management, November 3-5, 2015, Atlanta, Georgia, USA.
More presentations at http://swinecast.com/2015-niaa-symposium-antibiotics-stewardship-from-metrics-to-management
The document provides a commercial update for May 2016, including:
- Updates on programmes like sustainability and transformation partnerships, vanguards, and the Five Year Forward View.
- Information on changes to procurement regulations and the standard NHS contract for 2016/17.
- New features like "Our Insights" focusing on myths around competitive dialogue and submitting compliant tenders.
- Sections with commissioner updates, provider updates, and notices about procurement and contracts.
The document provides a commercial update for May 2016, including:
- STPs will require local health systems to collaborate on 5-year plans to improve quality, finances, and population health.
- Vanguards are sharing learning through podcasts on integrated care models.
- The Better Care Fund is being implemented for 2016/17 to further integrate health and social care.
- Capitation payments may be implemented in 2017 to support new care models.
- Emerging digital technologies may transform health and care delivery.
Opportunities and Barriers in Pharmaceutical Pricing: Average Manufacturer Pr...Epstein Becker Green
Part 2 of a webinar series that examines the average manufacturer price (“AMP”) Final Rule and its effect on drug pricing and contracting. Hosted by an Epstein Becker Green and EBG Advisors.
The long-awaited issuance of the Final Rule addressing AMP under the Medicaid Drug Rebate Program has provided clarity in some respects but left other issues open to interpretation. In the wake of the Final Rule, other regulatory developments are already showing signs of further impacting many of the same issues.
Using the AMP Final Rule as a baseline, we will address the evolution of some of the most significant issues affecting drug pricing and contracting. We hope you can attend one or both of the sessions in this two-part series.
In this session, Dr. Samuel R. Nussbaum, M.D., Strategic Consultant at EBG Advisors, and Lesley R. Yeung, Associate at Epstein Becker Green, will examine the pay-for-value and alternative approaches to pharmaceutical pricing. The speakers will discuss opportunities and barriers as well as highlight real-world examples.
http://www.ebglaw.com/events/the-effect-of-the-average-manufacturer-price-final-rule-on-drug-pricing-and-contracting-part-2-opportunities-and-barriers-in-pharmaceutical-pricing/
These materials have been provided for informational purposes only and are not intended and should not be construed to constitute legal advice. The content of these materials is copyrighted to Epstein Becker & Green, P.C. ATTORNEY ADVERTISING.
The Regulatory Policy Institute, based in Oxford, holds an annual conference on competition and regulation. At this year’s conference, OHE’s Jon Sussex described how the prescription medicines market in England is regulated for innovation.
The regulatory problem for the pharmaceutical market is different from that for utilities markets, transport, financial services and indeed markets for all other types of goods and services. The source of the regulatory problem for prescription medicines in the NHS is that the consumer (patient) neither decides which medicine is prescribed nor is responsible for paying for it. For other goods and services, the consumer decides and pays, as well as consumes. In the pharmaceutical market under the NHS, it is the payer who effectively decides the value of an innovation, not the patient.
The cost and risk in drug development are high. To determine how best to target its R&D efforts, the pharmaceutical industry needs clear signals about what innovation the health care payer, the NHS, values. The recent history of such signalling has been dominated in England by the actions of the National Institute for Health and Care Excellence (NICE), whose assessments also have considerable influence internationally. Moreover, although England represents only 2% of the world pharmaceutical market, its prices are use as a reference for pricing in other markets.
How NICE expresses the value of medicines can be viewed as a mean of regulating innovation. NICE always has based its decisions about value on the incremental cost to the tax-funded health and social care services of the additional quality-adjusted life years a new medicine offers to patients. During the last year, NICE has been consulting on ways to broaden its assessment of value, particularly on whether to take account of the burden of disease and wider societal impacts beyond QALYs. The decisions have not yet been made and the signal to potential pharmaceutical innovators remains fuzzy.
This EIU report has been commissioned by Gilead Sciences. It looks at health outcomes of treatment relative to cost and at the structure of Spanish healthcare delivery, the process of making healthcare more accountable in Spain, and the growth and adoption of value-based measures.
This document provides an update to a 2014 paper on integrating tobacco cessation medications into state and provincial quitlines. It summarizes trends showing an increase in quitlines offering medications from 70% in 2008 to 87% in 2012. The update reviews evidence that providing medications through quitlines increases their reach and effectiveness by improving quit rates. It describes current models for medication integration including information only, limited distribution, full distribution, and partnership distribution. Finally, it summarizes literature finding that medication use improves quit outcomes and increased call volumes when promoted.
The document discusses joint working between the pharmaceutical industry and the NHS to improve patient outcomes. It provides background on the changing healthcare environment and need for industry and NHS to build new relationships. It defines joint working as situations where pharmaceutical companies and the NHS pool skills and resources for patient-centered projects and share goals. Examples are provided of joint working projects between GSK and two NHS organizations to improve management of COPD. Key lessons for successful joint working include having clear objectives, engaging stakeholders, and being open and honest.
Efficacy of Nicotine Replacement Therapy (NRT) to Aid Cigarette Sm.docxtoltonkendal
Efficacy of Nicotine Replacement Therapy (NRT) to Aid Cigarette Smoking Cessation amongst Adults in United Kingdom
Introduction
Tobacco smoking is a major contributor to many serious diseases that eventually lead to death in the United Kingdom (UK). According to Office of National Statistics (ONS) (2017), 7.4 million of United Kingdom’s population are smokers and 19.7 percent of these smokers are adult with age-range of 25 to 34 years. Tobacco cigarettes contain nicotine. Nicotine changes the balance of two chemicals namely noreadrenaline and dopamine which are found in human the brain. The sudden change on the levels of these chemicals after inhalation may result in changes in mood which could result in reduction of stress, anxiety and increase in pleasure (National Health Service (NHS), 2018a). Transmission of nicotine by inhalation of tobacco is the fastest way of distributing nicotine into the bloodstream according to Action on Smoking and Health (ASH) (2019). Therefore, these facts indicate that smoking cigarettes could be profoundly addictive due to the rapid delivery of the desired effects to its users without taking into consideration any adverse effects on the human body and health.
Cigarette smoking harms human health; and stopping has proven hard to do alone. According to Health and Social Care Information Centre (HSCIC) (2017), in 2017 there were 146,234 people who started to try to quit smoking, only 49 percent successfully managed to stay away from using cigarretes and 33 percent of the individuals who successfully managed to stop smoking utilised licensed nicotine containing products. The government came up with tobacco control plan for England to assist its people to stop smoking; the elements of the plan include making tobacco more expensive, restraining tobacco related publicity, efficient control of tobacco products, developing alertness on harm caused by smoking and lowering the instance to be exposed to second-hand smoke (Public Health England, 2015).
Smoking cessation services and interventions are being offered by the NHS. Affirmed by National Institute for Health and Care Excellence (NICE) (2019), there are few evidenced-based interventions for smoking available in the UK for adults which include behavioural support, bupropion, nicotine replacement therapy (NRT), varenicline and very brief advices (VBA). These interventions are available to individuals who seek help through their general practitioner and to those who are being referred to health professionals for assistance; some of the interventions are combined to be able to achieve the desired goal which is to ultimately forgo smoking tobacco.
This paper will discuss the different kinds of NRT available for adults in the United Kingdom. Nicotine replacement therapy (NRT) includes few ways to supplement smoking. It helps to fight the urge to consume or inhale tobacco and also to reduce the effects of withdrawal. In addition, it will help individuals to slowly redu.
The document summarizes AGHA's advocacy campaigns in Uganda to promote access to essential medicines, including their "Stop-Stock-outs" campaign. It found frequent stock-outs of malaria and antibiotic drugs in rural health centers due to underfunding of the health sector. The campaign pressured the government and resulted in reports of shortages, commitments to purchase more drugs, and calls to increase health sector funding to 15% of the national budget.
Establish Pharmacovigilance Centres in hospital and National Programmes.pptxPiyushZala5
Three key points:
1) Pharmacovigilance centers play an important role in both hospitals and the pharmaceutical industry by monitoring adverse drug reactions and ensuring drug safety.
2) Establishing a pharmacovigilance center requires obtaining approvals, developing reporting forms, educating staff, creating a database to store reports, and networking with other organizations.
3) India has established a national pharmacovigilance program called PvPI coordinated by the Indian Pharmacopoeia Commission to monitor drug safety, expand reporting nationwide, and collaborate with other health programs.
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Office of Health Economics
This research presented in a poster at HTAi 2019, Cologne (Germany) by a team of OHE and IHE researchers, estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden. It concludes that considering the entire life-cycle, the value added by SGAs to the system is higher than the expected value estimated at launch. P&R decisions should consider how to measure, capture and take into account the value added by medicines over the long-run.
Author(s) and affiliation(s): Mikel Berdud (Office of Health Economics, London), Niklas Wallin-Bernhardsson (Institute for Health Economics, Stockholm), Bernarda Zamora (Office of Health Economics, London), Peter Lindgren (Institute for Health Economics, Stockholm), Adrian Towse (Office of Health Economics, London)
Event: HTAi 2019 Annual Meeting
Date: 18/06/2019
Location: Cologne, Germany
Các nguyên tắc sửa đổi về submit dữ liệu điện tử để apply cho các thuốc mới lưu hành tại Nhật Bản. Xem thêm các tài liệu khác trên kênh của Công ty Cổ phần Tư vấn Thiết kế GMP EU
Similar to Benefits case study summary – prescriptions dispensed in the community’ publication (20)
HSCIC/ESR Data Quality / Data Standards Road Shows 2015/16
The Health and Social Care Information Centre has hosted a series of road shows jointly with the Electronic Staff Record (ESR) Central Team and Health Education England to highlight developments in NHS workforce information, data standards and data quality.
Here are the slides presented at the fourth event, held at the Taunton Rugby Club, Taunton on 25th February 2016.
Data quality is all about collaborative working with a shared purpose and this is the main driver behind our road shows during 2015/16. Any efforts to improve data quality should have mutual benefits and should provide a platform for discourse between all involved. Collectively we can ensure that the data that is used to inform decisions about the workforce at local, regional and national level is as accurate as possible. Good data quality can't guarantee good decisions are made, but poor data quality will definitely increase the likelihood of poor decisions and poor outcomes.
SCIC/ESR Data Quality / Data Standards Road Shows 2015/16
The Health and Social Care Information Centre has hosted a series of road shows jointly with the Electronic Staff Record (ESR) Central Team and Health Education England to highlight developments in NHS workforce information, data standards and data quality.
Here are the slides presented at the third event, held at Bruntwood City Tower, Manchester on 1st March 2016.
Data quality is all about collaborative working with a shared purpose and this is the main driver behind our road shows during 2015/16. Any efforts to improve data quality should have mutual benefits and should provide a platform for discourse between all involved. Collectively we can ensure that the data that is used to inform decisions about the workforce at local, regional and national level is as accurate as possible. Good data quality can't guarantee good decisions are made, but poor data quality will definitely increase the likelihood of poor decisions and poor outcomes.
The document outlines the agenda for a data quality and data standards roadshow presented by the Health and Social Care Information Centre. Recent developments in NHS Jobs data quality and the workforce Minimum Data Set are discussed, including issues found and future plans. Future proposed changes to national workforce data standards and codes are also mentioned.
A benefits case study describing how Diabetes UK has used HSCIC's data and statistical outputs to inform the Putting Feet First campaign. https://www.diabetes.org.uk/Get_involved/Campaigning/Our-campaigns/Putting-feet-first/
The Health and Social Care Information Centre is hosting a series of road shows jointly with the Electronic Staff Record (ESR) Central Team and Health Education England to highlight developments in NHS workforce information, data standards and data quality.
Here are the slides presented at the second event, held at The Priory Rooms, Birmingham on 26th November 2015.
Data quality is all about collaborative working with a shared purpose and this is the main driver behind our road shows during 2015/16. Any efforts to improve data quality should have mutual benefits and should provide a platform for discourse between all involved. Collectively we can ensure that the data that is used to inform decisions about the workforce at local, regional and national level is as accurate as possible. Good data quality can't guarantee good decisions are made, but poor data quality will definitely increase the likelihood of poor decisions and poor outcomes.
For more information about future events, please contact the team at workforce.dq@hscic.gov.uk
Nicholas Oughtibridge (Principle Author of the Code of Practice for Confidential Information - HSCIC) spoke at the recent "Commissioning in Healthcare show (CiH 2015)".
Areas covered include:
· The role of the code of practice
· What is covered by the Code of Practice on Confidential Information?
· The seven steps in the life of a data collection
· Sharing confidential information with other people to meet legitimate needs
· Plans for revising the Code of Practice on Confidential Information
Julie Henderson (Head of Analytical Services - HSCIC) presented with Shaun Rowark (Technical Analyst, Quality Standards - NICE) at the recent "Commissioning in Healthcare show (CiH 2015) ".
Areas covered include:
· NICE quality standards: These are concise sets of prioritised statements designed to drive measurable quality improvements within a particular area of health or care. Derived from the best available evidence, they can enable commissioners to be confident that the services they are purchasing are high quality, cost effective and focused on driving up quality.
· Real life examples of how quality standards are being used by commissioners, possible barriers to implementation and advice on how to overcome these
· Data available from the HSCIC and how to use these to support the commissioning process
The Intelligent Data Tool (IDT) analyzes data from 14 million annual NHS Pathways calls to provide intelligence about symptom prevalence, performance, and service usage. It turns call data into dashboards that empower commissioners to manage 111/999 contracts by providing filters, symptom trends, and performance management summaries. The IDT is currently in beta testing and will provide wider access if the pilot is successful.
Andy Williams (Chief Executive - HSCIC) spoke at the recent "Healthcare Efficiency Through Technology Expo (HETT 2015)".
Areas covered include:
· Role and remit of the HSCIC
· Summary of important activity from the last 12 months
· HSCIC’s strategy 2015 - 2020
· The big delivery challenges the health and care system faces
Cleveland Henry (Director of NHS Choices - HSCIC) spoke at the recent "Healthcare Efficiency Through Technology Expo (HETT 2015)".
Areas covered include:
· How does analysis of NHS Choices usage help us to understand the public’s health and care information needs?
· What can web analytics and user feedback tell us about the most popular and useful content?
· How does the mass media agenda drive content consumption?
· How has the move to ‘mobile’ changed the demand for information?
· Where next for online information and transactions?
The document summarizes key findings from the 2014-15 Adult Social Care Outcomes Framework annual report. It found that the North East and South East of England had the highest social care-related quality of life scores, while London had the lowest. Overall, 77% of social care service users felt they had control over their daily lives. Several metrics showed declines from 2012-13 to 2014-15, including carer-reported quality of life (from 8.1 to 7.9), carer satisfaction with social services (from 43% to 41%), and the proportion of carers who found it easy to access service information (from 69% to 66%).
The Health and Social Care Information Centre is hosting a series of road shows jointly with the Electronic Staff Record (ESR) Central Team and Health Education England to highlight developments in NHS workforce information, data standards and data quality.
Here are the slides presented at the first event, held at the Royal Marsden NHS Foundation Trust on 1st October 2015.
Data quality is all about collaborative working with a shared purpose and this is the main driver behind our road shows during 2015/16. Any efforts to improve data quality should have mutual benefits and should provide a platform for discourse between all involved. Collectively we can ensure that the data that is used to inform decisions about the workforce at local, regional and national level is as accurate as possible. Good data quality can't guarantee good decisions are made, but poor data quality will definitely increase the likelihood of poor decisions and poor outcomes.
For more information about future events, please contact the team mailto:workforce.dq@hscic.gov.uk <mailto:workforce.dq@hscic.gov.uk>
The document discusses various health metrics and trends among young people in England. It notes that drinking, smoking, and drug use have decreased among secondary school pupils in the last decade. However, fewer children are meeting recommended levels of physical activity. Dental caries remain the most common hospital diagnosis for children aged 5-9. Referral rates for psychological therapies have increased and are twice as high for 15-19 year old female teenagers than males.
Presentation given relating to the HSCIC report 'Focus on the health and care of young people June 2015' by Kate Croft, HSCIC Head of Statistical Response Unit. This took place at the Health+Care event at London's ExCel, on Thursday 25 June 2015.
The document provides details on the Health and Social Care Information Centre's (HSCIC) business plan for 2015/16. It outlines the HSCIC's role, structure, values, strategy, key achievements in 2014/15, and commitments for 2015/16. The plan aims to support wider health system reform by ensuring data protection, establishing shared standards, implementing national services, supporting organizations to use technology and data, and making better use of health information. The commitments are designed to deliver benefits like improved data access and use, trusted statistics, essential technology infrastructure, and reduced data burdens.
CircleBath used PROMs data to identify areas for improvement in their hip and knee replacement procedures. They implemented changes such as enhanced recovery protocols and improved rehabilitation services. This contributed to CircleBath moving from below to above the England average for adjusted health gains on the Oxford Hip and Knee scores between 2011/12 and 2013/14, demonstrating improved patient outcomes.
This is the HSCIC's draft five-year strategy. A consultation is now open, until February 27th, to gather your feedback. Please have your say and help to shape our future. http://bit.ly/16o8zfk
A catalogue of fact sheets has been compiled in order to give journalists an idea of the breadth of statistical information available at the Health and Social Care Information Centre (HSCIC).
These fact sheets cover a range of subjects at a national level broken down by individual subject areas.
Download this fact sheet to understand more about "Contraception".
A catalogue of fact sheets has been compiled in order to give journalists an idea of the breadth of statistical information available at the Health and Social Care Information Centre (HSCIC).
These fact sheets cover a range of subjects at a national level broken down by individual subject areas.
Download this fact sheet to understand more about "Obesity".
More from The Health and Social Care Information Centre (20)
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)bkling
Your mindset is the way you make sense of the world around you. This lens influences the way you think, the way you feel, and how you might behave in certain situations. Let's talk about mindset myths that can get us into trouble and ways to cultivate a mindset to support your cancer survivorship in authentic ways. Let’s Talk About It!
Healthy Eating Habits:
Understanding Nutrition Labels: Teaches how to read and interpret food labels, focusing on serving sizes, calorie intake, and nutrients to limit or include.
Tips for Healthy Eating: Offers practical advice such as incorporating a variety of foods, practicing moderation, staying hydrated, and eating mindfully.
Benefits of Regular Exercise:
Physical Benefits: Discusses how exercise aids in weight management, muscle and bone health, cardiovascular health, and flexibility.
Mental Benefits: Explains the psychological advantages, including stress reduction, improved mood, and better sleep.
Tips for Staying Active:
Encourages consistency, variety in exercises, setting realistic goals, and finding enjoyable activities to maintain motivation.
Maintaining a Balanced Lifestyle:
Integrating Nutrition and Exercise: Suggests meal planning and incorporating physical activity into daily routines.
Monitoring Progress: Recommends tracking food intake and exercise, regular health check-ups, and provides tips for achieving balance, such as getting sufficient sleep, managing stress, and staying socially active.
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in CardiologyR3 Stem Cell
Dr. David Greene, founder and CEO of R3 Stem Cell, is at the forefront of groundbreaking research in the field of cardiology, focusing on the transformative potential of stem cell therapy. His latest work emphasizes innovative approaches to treating heart disease, aiming to repair damaged heart tissue and improve heart function through the use of advanced stem cell techniques. This research promises not only to enhance the quality of life for patients with chronic heart conditions but also to pave the way for new, more effective treatments. Dr. Greene's work is notable for its focus on safety, efficacy, and the potential to significantly reduce the need for invasive surgeries and long-term medication, positioning stem cell therapy as a key player in the future of cardiac care.
Unlocking the Secrets to Safe Patient Handling.pdfLift Ability
Furthermore, the time constraints and workload in healthcare settings can make it challenging for caregivers to prioritise safe patient handling Australia practices, leading to shortcuts and increased risks.
Michigan HealthTech Market Map 2024. Includes 7 categories: Policy Makers, Academic Innovation Centers, Digital Health Providers, Healthcare Providers, Payers / Insurance, Device Companies, Life Science Companies, Innovation Accelerators. Developed by the Michigan-Israel Business Accelerator
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)blessyjannu21
Neurological system includes brain and spinal cord. It plays an important role in functioning of our body. Encephalitis is the inflammation of the brain. Causes include viral infections, infections from insect bites or an autoimmune reaction that affects the brain. It can be life-threatening or cause long-term complications. Treatment varies, but most people require hospitalization so they can receive intensive treatment, including life support.
Letter to MREC - application to conduct studyAzreen Aj
Application to conduct study on research title 'Awareness and knowledge of oral cancer and precancer among dental outpatient in Klinik Pergigian Merlimau, Melaka'
We are one of the top Massage Spa Ajman Our highly skilled, experienced, and certified massage therapists from different corners of the world are committed to serving you with a soothing and relaxing experience. Luxuriate yourself at our spas in Sharjah and Ajman, which are indeed enriched with an ambiance of relaxation and tranquility. We could confidently claim that we are one of the most affordable Spa Ajman and Sharjah as well, where you can book the massage session of your choice for just 99 AED at any time as we are open 24 hours a day, 7 days a week.
Visit : https://massagespaajman.com/
Call : 052 987 1315
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareDr. David Greene Arizona
Explore the groundbreaking work of Dr. David Greene, a pioneer in regenerative medicine, who is revolutionizing the field of cardiology through stem cell therapy in Arizona. This ppt delves into how Dr. Greene's innovative approach is providing non-surgical, effective treatments for heart disease, using the body's own cells to repair heart damage and improve patient outcomes. Learn about the science behind stem cell therapy, its benefits over traditional cardiac surgeries, and the promising future it holds for modern medicine. Join us as we uncover how Dr. Greene's commitment to stem cell research and therapy is setting new standards in healthcare and offering new hope to cardiac patients.
Benefits case study summary – prescriptions dispensed in the community’ publication
1. v1.0
26/01/2016
Benefits case study summary – ‘Prescriptions Dispensed
in the Community’ publication
Case study purpose and publication uses
The purpose of this case study summary is to briefly describe how stakeholders have used the Prescriptions
Dispensed in the Community publication to inform analytical, reporting and contract negotiation activities.
Examples of such uses include:
Department of Health’s (DH’s) Medicines, Pharmacy and Industry division has used the 2013 and 2014
publication findings to inform the following analytical activities:
o the 2013 publication finding of 90.0% of all prescriptions dispensed free of charge was used to
request from the Business Services Authority (BSA) monthly breakdown of exemption numbers and
NIC for all exemption categories and pre-paid certificates. The resulting data fed into an estimate on
the impact of prescription charging fraud on revenue.
o the 2013 finding of 64.2% of prescriptions dispensed free of charge for age exemptions was used to
request from the HSCIC data, split across five age bands (and ‘all ages’), on the number of
prescriptions dispensed in 2013. This detailed data helped inform the development of a model to
better understand the demand for prescriptions.
o the 2014 publication finding of £376 million NIC for British National Formulary (BNF) 9.4: Oral
nutrition, which includes gluten-free products (e.g. gluten-free bread), was used to request, from the
HSCIC, item-level breakdown for BNF 9.4.1: Foods for special diets. The granular data reported
that, in 2014/15, 1.26 million items, at an NIC of £90.9 million, were dispensed for special diet foods.
Public Health England (PHE) established the English surveillance programme for antimicrobial utilisation
and resistance (ESPAUR), in response to the UK Five Year Antimicrobial Resistance Strategy 2013 to
2018. In ESPAUR’s first report (2014), PHE used the 2013 publication’s antibacterial data (BNF 5.1) to
set out ten-year dispensing trends for various antibacterial drugs, including penicillin and macrolides.
NHS England used the publication to:
o negotiate with the Pharmaceutical Services Negotiating Committee (PSNC) on the future role of
pharmacies and pharmacy contracts. PSNC also used the publication for the same purposes.
o help assess the effectiveness of NHS England’s role in supporting the UK Five Year Antimicrobial
Resistance Strategy 2013 to 2018.
The PSNC used the publication to help monitor how much remuneration community pharmacies are
expected to generate from prescription dispensing activities.
The Royal Pharmaceutical Society (RPS) used the publication to advocate the role and importance of
community pharmacists, through approaches such as describing publication findings on RPS website.
Prescriptions Dispensed in the Community publication overview
Annually, the Health and Social Care Information Centre (HSCIC) produces the Prescriptions Dispensed in
the Community publication, which highlights national findings, changes and trends on prescriptions
dispensed in the community. The most recent publication, Prescriptions Dispensed in the Community,
England 2004-2014, was released in July 2015 and reported various findings, including:
1.1 billion prescription items, at a net ingredient cost (NIC) of £8.9 billion, were dispensed in 2014.
89.9% of all prescription items were dispensed free of charge in 2014.
The annual publication is aimed at enabling stakeholders to understand national patterns and trends in
prescriptions dispensed and, through subsequent analysis of granular data, investigate improvement
opportunities and concerns. In some cases, the investigations will lead to changes in prescribing and
dispensing services, with the ultimate aim of generating improvements (benefits).
Web link
The case study summary can be accessed at http://www.hscic.gov.uk/benefitscasestudies/publications